PMID- 37075672
OWN - NLM
STAT- MEDLINE
DCOM- 20230601
LR  - 20230601
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 119
DP  - 2023 Jun
TI  - EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for 
      first-line treatment of advanced non-small cell lung carcinoma: A systematic 
      review and meta-analysis.
PG  - 110001
LID - S1567-5769(23)00322-3 [pii]
LID - 10.1016/j.intimp.2023.110001 [doi]
AB  - PURPOSE: Immuno-combination therapy is emerging as an effective treatment for 
      advanced non-small cell lung carcinoma (NSCLC). However, compared to monotherapy, 
      such as monoclonal antibodies or kinase inhibitors, whether combination therapy 
      can enhance antitumor efficacy or alleviate side effects remains unclear. 
      METHODS: A systematic literature search was undertaken using the PubMed, Embase, 
      Web of Science and Cochrane Central Register of Controlled Trials databases to 
      identify eligible studies concentrating on treatment with erlotinib or erlotinib 
      plus monoclonal antibodies in NSCLC patients published between January 2017 and 
      June 2022. The primary outcomes included progression-free survival (PFS), overall 
      survival (OS), response rate (RR) and treatment-related adverse events (AEs). 
      RESULTS: Seven independent randomized, controlled clinical trials including 1513 
      patients were obtained for the final analysis. Erlotinib plus monoclonal 
      antibodies was significantly associated with the improvement of PFS (hazards 
      ratio [HR], 0.60; 95% CI 0.53-0.69; z = 7.59, P < 0.01) and with moderate 
      performance regarding OS (HR, 0.81; 95% CI 0.58-1.13; z = 1.23, P = 0.22) and RR 
      (odds ratio [OR], 1.25; 95% CI 0.98-1.59; z = 1.80, P = 0.07), irrespective of 
      EGFR mutation status. In the safety evaluation, erlotinib plus monoclonal 
      antibodies had a markedly higher occurrence of adverse events (AEs) of Clavien 
      grade 3 or higher (OR, 3.32; 95% CI 2.66-4.15; z = 10.64, P < 0.01). CONCLUSION: 
      Compared with erlotinib alone, combination therapy (erlotinib plus monoclonal 
      antibodies) was associated with significantly improved PFS in NSCLC therapy, 
      accompanied by increased treatment-related AEs. REGISTRATION: Our systematic 
      review protocol was registered in the PROSPERO international register of 
      systematic reviews (CRD42022347667).
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Liu, Mohan
AU  - Liu M
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.
FAU - Xiao, Kaiwen
AU  - Xiao K
AD  - Department of Urology, Institute of Urology (Laboratory of Reconstructive 
      Urology), West China Hospital, Sichuan University, Chengdu, Sichuan, China.
FAU - Yang, Li
AU  - Yang L
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China. 
      Electronic address: 2021324065095@stu.scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230417
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Carcinoma, Non-Small-Cell Lung/pathology/therapy
MH  - ErbB Receptors/genetics
MH  - Erlotinib Hydrochloride/therapeutic use
MH  - *Lung Neoplasms/genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Erlotinib
OT  - Meta-analysis immunotherapy
OT  - Monoclonal antibodies
OT  - NSCLC
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/20 00:41
MHDA- 2023/06/01 06:42
CRDT- 2023/04/19 18:07
PHST- 2022/11/14 00:00 [received]
PHST- 2023/03/04 00:00 [revised]
PHST- 2023/03/06 00:00 [accepted]
PHST- 2023/06/01 06:42 [medline]
PHST- 2023/04/20 00:41 [pubmed]
PHST- 2023/04/19 18:07 [entrez]
AID - S1567-5769(23)00322-3 [pii]
AID - 10.1016/j.intimp.2023.110001 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Jun;119:110001. doi: 10.1016/j.intimp.2023.110001. Epub 
      2023 Apr 17.